Evidence map›Paper›PMID 25996182›Full record

ReviewHuman vaccines & immunotherapeutics2015

Oncolytic viruses: From bench to bedside with a focus on safety.

Pascal R A Buijs, Judith H E Verhagen, Casper H J van Eijck, Bernadette G van den Hoogen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. CEA vaccines.Human vaccines & immunotherapeutics · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pascal R A Buijsa Department of Surgery; Erasmus MC; University Medical Center ; Rotterdam , The Netherlands.
Judith H E Verhagen
Casper H J van Eijck
Bernadette G van den Hoogen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic viruses are a relatively new class of anti-cancer immunotherapy agents. Several viruses have undergone evaluation in clinical trials in the last decades, and the first agent is about to be approved to be used as a novel cancer therapy modality. In the current review, an overview is presented on recent (pre)clinical developments in the field of oncolytic viruses that have previously been or currently are being evaluated in clinical trials. Special attention is given to possible safety issues like toxicity, environmental shedding, mutation and reversion to wildtype virus.

Indexed as

Oncolytic VirotherapyOncolytic VirusesClinical Trials as TopicHumansTranslational Research, BiomedicalVirus SheddingcancerCAR, Coxsackie Adenovirus receptorCD, cytosine deaminaseCEA, carcinoembryonic antigencrHAdV, conditionally replicating HAdVCVA, Coxsackievirus type ADAF, decay accelerating factorDNA, DNAdsDNA, double stranded DNAdsRNA, double stranded RNAEEV, extracellular enveloped virusEGF, epidermal growth factorEGF-R, EGF receptorEMA, European Medicines AgencyenvironmentFDA, Food and Drug AdministrationGBM, glioblastoma multiformeGM-CSF, granulocyte-macrophage colony-stimulating factorHAdV, Human (mast)adenovirusHA, hemagglutininHER2, human epidermal growth factor receptor 2hIFNβ, human IFN βHSV, herpes simplex virusICAM-1, intercellular adhesion molecule 1IFN, interferonimmunotherapyIRES, internal ribosome entry siteKb, kilobase pairsKRAS, Kirsten rat sarcoma viral oncogene homologMeV, Measles virusmORV, Mammalian orthoreovirusmORV-T3D, mORV type 3 DearingMuLV, Murine leukemia virusNDV, Newcastle disease virusNIS, sodium/iodide symporterNSCLC, non-small cell lung carcinomaoHSV, oncolytic HSVoncolytic virotherapyoncolytic virusOV, oncolytic virusPEG, polyethylene glycolPKR, protein kinase RPV, Polio virusRb, retinoblastomaRCR, replication competent retrovirusRCT, randomized controlled trialrdHAdV, replication-deficient HAdVreviewRGD, arginylglycylaspartic acid (Arg-Gly-Asp)RNA, ribonucleic acidsafetysheddingssRNA, single stranded RNASVV, Seneca Valley virusTGFα, transforming growth factor αtk, thymidine kinaseVGF, Vaccinia growth factorVSV, Vesicular stomatitis virusVV, Vaccinia virus

Identifiers

PMID25996182
PMCPMC4514197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.